Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning! We’re closing in on CMS’s deadline for 2027 Medicare-negotiated drug prices. Plus, we see a break from precedent in how the FDA selects priority review vouchers, and more.
Can a GLP-1 drug slow Alzheimer’s disease? Nope
Novo Nordisk said this morning that a pair of large, placebo-controlled clinical trials testing an oral version of its GLP-1 drug semaglutide failed to slow the cognitive decline of participants with Alzheimer’s disease.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply